Alphamab Oncology — Board/Management Information 2021

Aug 27, 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [172 x 40] intentionally omitted <==

ALPHAMAB ONCOLOGY 康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR

RESIGNATION OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “ Board ”) of directors (the “ Directors ”) of Alphamab Oncology (the “ Company ”) hereby announces that Dr. JIANG Hualiang (蔣華良) (“ Dr. Jiang ”) has tendered his resignation from the position as an independent non-executive Director, a member of the nomination committee and the strategy committee under the Board with effect from August 27, 2021 due to personal work arrangements.

Dr. Jiang has confirmed that he has no disagreement with the Board and there is no other matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “ Stock Exchange ”).

The Board would like to take this opportunity to express its gratitude to Dr. Jiang for his valuable contributions to the Company during his tenure of office.

APPOINTMENT OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board further announces that Dr. GUO Zijian (郭子建) (“ Dr. Guo ”) has been appointed as an independent non-executive Director and a member of the nomination committee and the strategy committee under the Board with effect from August 27, 2021.

The biographical details of Dr. Guo are as follows:

Dr. GUO Zijian (郭子建), aged 59, has been serving as a professor of School of Chemistry and Chemical Engineering of Nanjing University (南京大學化學化工學院) since May 1999. From October 1996 to April 1999, he was a research associate at the University of Edinburgh in the United Kingdom. Dr. Guo was granted the Outstanding Achievement Award by Asian Society of Biological Inorganic Chemistry (亞洲生物無機化學會) in October 2020. He won the Luigi Sacconi Medal from the Italian Chemical Society in September 2016. Dr. Guo was awarded the First Prize of China’s State Natural Science Award (國家自然科學一等獎) by Ministry of Education of the People’s Republic of China (中華人民共和國教育部) in February 2016. Dr. Guo received his doctor degree from the University of Padova in Italy in September 1994 and worked as a postdoctoral research fellow at Birkbeck College of the University of London in the United Kingdom until June 1996.

1

The Company and Dr. Guo entered into a letter of appointment, with an initial term of three years from August 27, 2021, which is subject to retirement by rotation and re-election at the annual general meeting of the Company pursuant to the articles of association of the Company, or vacation from office pursuant to any applicable laws from time to time. Dr. Guo is entitled to receive a director’s fee of RMB350,000 per annum which is subject to review by the Board with reference to his duties in the Company.

As of the date of this announcement, Dr. Guo does not hold any other position with the Company or its subsidiaries, nor does he have any relationship with any Directors, senior management, substantial shareholder or controlling shareholders (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the “ Listing Rules ”)) of the Company. He has not held any directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years. Dr. Guo does not have any interest in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Dr. Guo has not been subject to any penalty or punishment imposed by the China Securities Regulatory Commission or any other relevant authorities or stock exchanges.

Dr. Guo has confirmed that he has met the independence guidelines set out in Rule 3.13 of the Listing Rules.

Save as disclosed above, Dr. Guo has confirmed that there is no other matter relating to his appointment that needs to be brought to the attention of the shareholders of the Company, and there is no other information that needs to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to extend its warmest welcome to Dr. Guo for his appointment to the Board.

By Order of the Board Alphamab Oncology Dr. XU Ting Chairman and Executive Director

Hong Kong, August 27, 2021

As at the date of this announcement, the Board comprises Dr. XU Ting as the Chairman and Executive Director and Ms. LIU Yang as Executive Director, Mr. XU Zhan Kevin and Mr. QIU Yu Min as Non-executive Directors, and Dr. GUO Zijian, Mr. WEI Kevin Cheng and Mr. WU Dong as Independent Non-executive Directors.

2